Evaluating Local Thermotherapy Using Electric Heat Pads as Treatment
for Mild-to-Moderate COVID-19 to Prevent Disease Progression
Led by Instituto Nacional de Perinatologia · Updated on 2020-11-05
274
Participants Needed
3
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of local thermotherapy as a treatment to help control mild-to-moderate COVID-19, caused by the SARS-CoV-2 virus. This virus is a positive-sense single-stranded RNA virus responsible for a global pandemic with varying fatality rates. Raising the temperature on affected areas may inhibit viral replication by producing small interfering RNAs that block viral transcription. Thermotherapy has been previously used to target RNA viruses, cancer cells, and parasitic infections, which supports its potential use against COVID-19 to reduce viral load and aid the immune response.
The study compares two groups one receiving usual hospital care plus an electric heat pad applied to the chest for 90 minutes twice daily over 5 days, and the other receiving usual hospital care alone. The heat pad raises the skin temperature to 40-42 0C, a range expected to facilitate virus elimination without causing discomfort. The electric cushion is a commercially available device widely used for muscle pain and arthritis treatment.
Participants will undergo evaluations over 28 days to monitor disease progression and other health outcomes such as mortality, time to severe or critical COVID-19, hospitalization duration, oxygen requirement, and adverse events. Clinical status will be assessed using scales like the National Early Warning Score 2 NEWS-2, and safety and tolerance of the thermotherapy will be tracked. The trial is randomized and open-label, with follow-up visits occurring at multiple time points during and after the treatment period.
CONDITIONS
Brief Title
Local Thermotherapy for Patients With Mild-to-moderate COVID-19
Research Team
N
Norma del Carmen Galindo Sevilla, PhD
J
Javier Mancilla-Galindo, MBBS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Symptoms of mild or moderate COVID-19, including fever, cough, shortness of breath, or other listed symptoms
Mild COVID-19: Peripheral oxygen saturation (SaO2) ≥94% (≥90% in Mexico City and Guadalajara) without severe disease
Moderate COVID-19: Pneumonia with risk factors, SaO2 ≥94% (≥90% in Mexico City and Guadalajara) on up to 3 L/min supplemental oxygen, no severe or critical disease
Symptoms started 5 days or less before enrollment
Ability to understand and accept randomization and procedures
You will not qualify if you...
Suspected or confirmed pregnancy
Severe worsening of any underlying diseases
Previous COVID-19 diagnosis with full symptom resolution for at least 2 days
Severe COVID-19: tachypnea ≥30 breaths/min, SaO2 ≤93% (≤89% in Mexico City and Guadalajara) with up to 3 L/min oxygen, or PaO2/FiO2 ratio <300
Need for ≥4 L/min supplemental oxygen within first 24 hours of hospitalization
Two negative tests for SARS-CoV-2
Intolerance to thermotherapy requiring intervention stop
Transfer to another medical unit within first 5 days of study inclusion
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 5 days
Participants receive local thermotherapy using an electric heat pad applied on the thorax for 90 minutes, twice daily, for 5 days, in addition to usual in-hospital care.
Daily visits during treatment period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Long-Term Follow-Up Study of People with Asymptomatic or Diagnosed COVID-19 Infections in Shanghai
Randomized Study of a T Follicular Helper Targeting Genetic Vaccine Strategy to Induce Broad and Durable Immune Responses Against COVID-19
Study of Astepro Nasal Spray to Treat Early COVID-19 in Vaccinated Adults
Real-World Study of Paxlovid Treatment in Hospitalized Patients with COVID-19
Safety and Immune Response Study of OCU500 SARS-CoV-2 Booster Vaccine Given Intranasally or by Inhalation in Previously Vaccinated Adults
Study to Understand Long-Term Lung Effects After Severe COVID-19 Infection
Tracking Lung Health and Immune Responses Over One Year
Post-Marketing Study to Monitor Safety and Effectiveness of PAXLOVID in Adults at High Risk of Severe COVID-19
Improving COVID-19 and Flu Vaccine Acceptance in Pennsylvania Prisons Through Community Engagement and Rapid Testing of Interventions
Study of Chronic Antihistamine and Amantadine Treatments in COVID-19 Outcomes
Study of Arginine Replacement Therapy for Children and Young Adults Hospitalized With COVID-19 to Improve Mitochondrial Function
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Identification and characterization of microRNAs from in vitro-grown pear shoots infected with Apple stem grooving virus in response to high temperature using small RNA sequencing.